Skip to main content
SpringerLink
Log in

Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort

  • Original Paper
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Purpose

The burden of extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae (ESBL-E) is growing worldwide. We aimed to determine the financial disease burden attributable to ESBL-positive species in cases of bloodstream infection (BSI) due to K. pneumoniae and E. coli.

Methods

We conducted a cohort study on patients with BSI due to K. pneumoniae or E. coli between 2008 and 2011 in our institution. Data were collected on true hospital costs, length of stay (LOS), basic demographic parameters, underlying diseases as Charlson comorbidity index (CCI) and ESBL positivity of the pathogens. Multivariable regression analysis on hospital costs and length of stay was performed.

Results

Overall we found 1,851 consecutive cases of ESBL-E BSI, 352 (19.0 %) cases of K. pneumoniae BSI and 1,499 (81.0 %) cases of E. coli BSI. Sixty-six of E. coli BSI (18.8 %) and 178 of K. pneumoniae BSI (11.9 %) cases were due to ESBL-positive isolates, respectively (p = 0.001). 830 (44.8 %) cases were hospital-onset, 215 (61.1 %) of the K. pneumoniae and 615 (41.0 %) of the E. coli cases (p < 0.001). In-hospital mortality was overall 19.8, 25.0 % in K. pneumoniae cases and 18.5 % in E. coli cases (p = 0.006). Increased hospital costs and length of stay were significantly associated to BSI with ESBL-positive K. pneumoniae.

Conclusion

In contrast to BSI due to ESBL-positive E. coli, cases of ESBL-positive K. pneumoniae BSI were associated with significantly increased costs and length of stay. Infection prevention measures should differentiate between both pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm: ECDC. 2013.

  2. Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis. 2012;25:371–7.

    Article  PubMed  Google Scholar 

  3. Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the nonoutbreak setting: a systematic review. Am J Infect Control. 2011;39:599–601.

    Article  PubMed  Google Scholar 

  4. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.

    Article  PubMed  Google Scholar 

  5. Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by E. coli and influence of extended-spectrum-beta-lactamase positivity and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum beta-lactamase-positive Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol. 2013;34:133–43.

    Article  PubMed  Google Scholar 

  7. Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum β-lactamase positivity in cases of E. coli bloodstream infection. J Glob Antimicrob Resist. 2014.

  8. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, et al. Transmission dynamics of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012;55:967–75.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase-positive Enterobacteriaceae without contact isolation. Clin Infect Dis. 2012;55:1505–11.

    Article  PubMed  Google Scholar 

  11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

    Article  CAS  PubMed  Google Scholar 

  12. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Clinical and Laboratorical Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratorical Standards Institute (CLSI), Wayne, PA, USA [serial on the Internet]. 2012; Twenty-second Informational Supplement M100–S22.

  14. Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) positive bacteria in China. Curr Med Res Opin. 2010;26:1443–9.

    Article  PubMed  Google Scholar 

  15. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-positive E. coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.

    Article  PubMed  Google Scholar 

  16. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to E. coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66:398–407.

    Article  PubMed  Google Scholar 

  17. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase positivity in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20.

    Article  CAS  PubMed  Google Scholar 

  18. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase positive Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2014.

Download references

Acknowledgments

We would like to thank Georg Pilarsky, Sebastian Kruse and Oleg Jarychkivski for their excellent work in SQL programming and database management. We also thank Ryan Plocher for his service as language consultant.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Hygiene and Environmental Medicine, National Reference Center for the Surveillance of Nosocomial Infections, Charité Universitätsmedizin Berlin, Hindenburgdamm 27, 12203, Berlin, Germany

    R. Leistner, S. Gürntke, C. Sakellariou, L. A. Denkel, P. Gastmeier & F. Schwab

  2. Department of Medical and Financial Controlling, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

    A. Bloch

Authors
  1. R. Leistner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Gürntke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Sakellariou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. A. Denkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Bloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Gastmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Leistner.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 49 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leistner, R., Gürntke, S., Sakellariou, C. et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection 42, 991–997 (2014). https://doi.org/10.1007/s15010-014-0670-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-014-0670-9

Keywords

Search

Navigation